Veracyte, Inc.
$33.45
▼
-0.46%
2026-04-21 10:05:01
www.veracyte.com
NGM: VCYT
Explore Veracyte, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.63 B
Current Price
$33.45
52W High / Low
$50.71 / $22.61
Stock P/E
39.66
Book Value
$16.5
Dividend Yield
—
ROCE
5.82%
ROE
5.34%
Face Value
—
EPS
$0.82
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
755
Beta
1.96
Debt / Equity
3.03
Current Ratio
8.15
Quick Ratio
7.81
Forward P/E
17.55
Price / Sales
4.78
Enterprise Value
$2.1 B
EV / EBITDA
24.85
EV / Revenue
4.05
Rating
Buy
Target Price
$47
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 2. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 3. | Natera, Inc. | $206.53 | — | $29.47 B | — | -15.84% | -14.32% | $256.36 / $131.81 | $12.26 |
| 4. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
| 5. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
| 6. | bioAffinity Technologies, Inc. | $2.69 | — | $12.87 M | — | -131.93% | -3.02% | $17.44 / $0.69 | $1.62 |
| 7. | RadNet, Inc. | $57.85 | — | $4.48 B | — | 2.63% | 1.37% | $85.84 / $46.76 | $14.08 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 140.64 M | 131.87 M | 130.16 M | 114.47 M | 118.63 M | — |
| Operating Profit | 39.91 M | 23.11 M | 14.31 M | 1.16 M | 6.03 M | — |
| Net Profit | 41.15 M | 19.14 M | -0.98 M | 7.05 M | 5.11 M | — |
| EPS in Rs | 0.52 | 0.24 | -0.01 | 0.09 | 0.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 517.14 M | 445.76 M | 361.05 M | 296.54 M |
| Operating Profit | 78.28 M | 19.51 M | -17.45 M | -35.34 M |
| Net Profit | 66.35 M | 24.14 M | -74.4 M | -36.56 M |
| EPS in Rs | 0.84 | 0.3 | -0.94 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.41 B | 1.3 B | 1.11 B | 1.16 B |
| Total Liabilities | 96.44 M | 124.07 M | 70.8 M | 81.22 M |
| Equity | 1.31 B | 1.18 B | 1.04 B | 1.08 B |
| Current Assets | 488.38 M | 372.27 M | 285.62 M | 248.64 M |
| Current Liabilities | 59.94 M | 78.63 M | 61.24 M | 62.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 136.31 M | 75.1 M | 44.22 M | 7.54 M |
| Investing CF | -9.21 M | -56.27 M | 15.11 M | -29.39 M |
| Financing CF | -4.22 M | 4.9 M | 2.84 M | 3.49 M |
| Free CF | 126.63 M | 63.81 M | 34.26 M | -1.01 M |
| Capex | -9.68 M | -11.29 M | -9.96 M | -8.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 23.46% | 21.76% | — | — |
| Earnings Growth % | 132.44% | -103.51% | — | — |
| Profit Margin % | 5.41% | -20.61% | -12.33% | — |
| Operating Margin % | 4.38% | -4.83% | -11.92% | — |
| Gross Margin % | 66.88% | 63.62% | 59.24% | — |
| EBITDA Margin % | 11.04% | -13.68% | -3.47% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.